Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05548556 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
A Phase 2 study of Facioscapulohumeral Muscular Dystrophy (FSHD), sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 10
- Study locations
NCT05548556: Active Phase 2 study of Facioscapulohumeral Muscular Dystrophy (FSHD), sponsored by Hoffmann-La Roche.
NCT05548556 is a Phase 2 study of Facioscapulohumeral Muscular Dystrophy (FSHD) that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 51 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05548556, a Phase 2 study of Facioscapulohumeral Muscular Dystrophy (FSHD), is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RO7204239
Study Locations (10)
Other
- Rigshospitalet - København Ø
- National Hospital for Neurology and Neurosurgery, - London
- Royal Victoria Infirmary - Newcastle upon Tyne
California
- University of Irvine Medical Center (UCIMC) - Orange
Colorado
- Regents of the University of Colorado - Aurora
Kansas
- University of Kansas Medical Center - Fairway
Maryland
- Kennedy Krieger Institute - Baltimore
Virginia
- Virginia Commonwealth University Medical Center - Richmond
Lazio
- Policlinico Universitario Agostino Gemelli - Rome
Lombardy
- Asst Grande Ospedale Metropolitano Niguarda - Milan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-02-07 |
| Est. Completion | 2026-10-23 |
| Phase | Phase 2 |
What the registry record for NCT05548556 still lists
NCT05548556 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Facioscapulohumeral Muscular Dystrophy (FSHD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05548556 lists 10 locations in 8 states (Other, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT05548556 about?
NCT05548556 is a clinical study titled "A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy". The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).
What is the current status of trial NCT05548556?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2023-02-07. Estimated completion is 2026-10-23.
What conditions does trial NCT05548556 study?
This clinical trial studies the following conditions: Facioscapulohumeral Muscular Dystrophy (FSHD).
What interventions are being tested in trial NCT05548556?
The interventions under investigation include: Placebo (DRUG), RO7204239 (DRUG).
Who is sponsoring clinical trial NCT05548556?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05548556 being conducted?
This trial has 10 study locations across California, Colorado, Kansas, Maryland, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Facioscapulohumeral Muscular Dystrophy (FSHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05548556's enrollment target sits among peer trials
51 1190th of 2000 higher than 806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI